Seegene partners with Springer Nature to develop 15 diagnostic reagents
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Seegene announced on Monday that it began recruiting applicants for its Open Innovation Program with Springer Nature. The program consists of 15 designated tasks to develop 15 new syndromic quantitative polymerase chain reaction (PCR) diagnostic reagents for specific conditions including urinary tract infections, dermatophytosis, sexually transmitted infections, and vaginitis. Seegene and Springer Nature will select clinical trial participants by the end of October and hopes to start reagent development in March 2024, when the selection process is due to be completed. Clinical research participants will be grouped into teams of at least two, including Ph.D. level personnel, working at universities or research institutions. The selected participants will also receive a maximum of $600,000 per project. A Seegene official said that “Although Seegene will lead the first program, participants will be in charge of the entire process from the initial development stages to clinical validation moving forward.”
Seegene inked a partnership agreement for technology sharing with Springer Nature in June. Under the agreement, Seegene will share its diagnostic and data analysis technology, known as the OneSystem™ Business, with leading companies in various countries and engage scientists from around the world to develop customized diagnostic products tailored to local needs. With this collaboration, Seegene will be able to leverage Springer Nature’s credibility to establish a global network of experts. Nature plans to showcase Seegene’s reagent development projects to the scientific community in the publication, enabling projects to be commercialized by combining the company’s technological prowess with global experts’ ideas and research outcomes.
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- “이륙 1분 뒤 ‘펑’, 기체가 갑자기”…169명 태운 中비행기에 무슨일이 - 매일경제
- 5년 후 5000만원 목돈…“9월 청년도약계좌, 오늘부터 신청하세요” - 매일경제
- 평균연봉 1억 넘는데, 줄퇴사…‘신의 직장’ 산업은행 2030 이탈 심각 - 매일경제
- 주차장서 롤스로이스 ‘쿵’...“괜찮다”는 피해 차주의 정체 - 매일경제
- ‘흰검 모나미룩’도 이상봉 만나면…“국민 볼펜, K몽블랑될 것” - 매일경제
- SKY도 버리고 떠난다…‘의대 공화국’이 만든 자퇴·휴학·편입 열풍 [핫이슈] - 매일경제
- 한동훈 장관과 초딩의 찐우정…‘꼬부기’ 받고 ‘모비딕’ 보냈다 - 매일경제
- 경복궁 불타자 고종 머물었던 이곳…6년만에 개방한다는데 - 매일경제
- [속보] 8월 소비자물가 3.4% 상승…4개월 만에 최대폭 - 매일경제
- 황인범, 세르비아 명문 즈베즈다 이적 “亞 최고 선수 온다” [오피셜] - MK스포츠